Resmetirom

302 - Confronting a metabolic epidemic: how to prevent, diagnose, & manage liver disease

Peter Attia MD

A thyroid hormone receptor agonist showing promise in phase three clinical trials for MASLD, targeting fibrosis and steatosis.